Cargando…
The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463672/ https://www.ncbi.nlm.nih.gov/pubmed/25984599 http://dx.doi.org/10.3390/ijms160510715 |
_version_ | 1782375813715329024 |
---|---|
author | Bielecka-Dabrowa, Agata Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Misztal, Małgorzata Rysz, Jacek Banach, Maciej |
author_facet | Bielecka-Dabrowa, Agata Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Misztal, Małgorzata Rysz, Jacek Banach, Maciej |
author_sort | Bielecka-Dabrowa, Agata |
collection | PubMed |
description | We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, the incremental predictive value of the following biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C (CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β (TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative value for HF was observed for NT-proBNP (area under the receiver operating characteristic curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis we found that CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L and NGAL > 39.9 ng/mL were significant predictors of overt HF. There was only a small improvement in predictive ability of the multi-biomarker panel including the four biomarkers with the best performance in the detection of HF—NT-proBNP, TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, CysC) give additive prognostic value for incident HF in hypertensive patients compared to NT-proBNP alone. |
format | Online Article Text |
id | pubmed-4463672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44636722015-06-16 The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension Bielecka-Dabrowa, Agata Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Misztal, Małgorzata Rysz, Jacek Banach, Maciej Int J Mol Sci Article We assessed the predictive ability of selected biomarkers using N-terminal pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive patients with or without overt heart failure, the incremental predictive value of the following biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C (CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β (TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative value for HF was observed for NT-proBNP (area under the receiver operating characteristic curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis we found that CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L and NGAL > 39.9 ng/mL were significant predictors of overt HF. There was only a small improvement in predictive ability of the multi-biomarker panel including the four biomarkers with the best performance in the detection of HF—NT-proBNP, TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, CysC) give additive prognostic value for incident HF in hypertensive patients compared to NT-proBNP alone. MDPI 2015-05-12 /pmc/articles/PMC4463672/ /pubmed/25984599 http://dx.doi.org/10.3390/ijms160510715 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bielecka-Dabrowa, Agata Gluba-Brzózka, Anna Michalska-Kasiczak, Marta Misztal, Małgorzata Rysz, Jacek Banach, Maciej The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title_full | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title_fullStr | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title_full_unstemmed | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title_short | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension |
title_sort | multi-biomarker approach for heart failure in patients with hypertension |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463672/ https://www.ncbi.nlm.nih.gov/pubmed/25984599 http://dx.doi.org/10.3390/ijms160510715 |
work_keys_str_mv | AT bieleckadabrowaagata themultibiomarkerapproachforheartfailureinpatientswithhypertension AT glubabrzozkaanna themultibiomarkerapproachforheartfailureinpatientswithhypertension AT michalskakasiczakmarta themultibiomarkerapproachforheartfailureinpatientswithhypertension AT misztalmałgorzata themultibiomarkerapproachforheartfailureinpatientswithhypertension AT ryszjacek themultibiomarkerapproachforheartfailureinpatientswithhypertension AT banachmaciej themultibiomarkerapproachforheartfailureinpatientswithhypertension AT bieleckadabrowaagata multibiomarkerapproachforheartfailureinpatientswithhypertension AT glubabrzozkaanna multibiomarkerapproachforheartfailureinpatientswithhypertension AT michalskakasiczakmarta multibiomarkerapproachforheartfailureinpatientswithhypertension AT misztalmałgorzata multibiomarkerapproachforheartfailureinpatientswithhypertension AT ryszjacek multibiomarkerapproachforheartfailureinpatientswithhypertension AT banachmaciej multibiomarkerapproachforheartfailureinpatientswithhypertension |